

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: FIV-34F10 PR

Catalog Number: 3711

Lot Number: 130254

Release Category: B

Provided: 5 μg of dried purified DNA stabilized in DNAstable *PLUS*

Description: The FIV-34F10 PR coding region was used in conjunction with clonable primers in a

PCR reaction, then cloned into the NdeI-HindIII region of PT7-7.

Special Characteristics:

This construct is 2775 bp including the insert.

The PR coding region of FIV-34F10 protease was modified at three sites (G5→I; N55→T; C84→K) to produce an autoproteolysis-resistant PR. Protease expression is IPTG inducible. The protease will facilitate structural, enzymatic, and drug efficacy studies. GenBank #M25729. The infectious

molecular clone FIV-34F10 is also available.

Sequence file lot 130254

This reagent is currently being provided as dried purified DNA stabilized in DNAstable *PLUS*. Please see the notice for additional information and the protocol for reconstitution of dried DNA

reagents. Dried DNA Notice

Recommended Storage:

Keep the reagent at room temperature in a dry storage cabinet or in a moisture

barrier bag.

Contributor: Dr. John Elder

References: Laco GS, et al. *J Virol* **71**:5505, 1997.

Talbott RL, et al. Proc Natl Acad Sci USA 86:5743, 1989.

Elder JH, et al. *J Virol* **67**:1869, 1993.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 03/27/2020 Page 1 of 2

NOTE:	Acknowledgment for	publications should read	l "The following reagent was obtained	t
-------	--------------------	--------------------------	---------------------------------------	---

through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: FIV-34F10 PR from Dr. John Elder (cat# 3711)." Also include the references cited above in any publications.

Last Updated: March 27, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 03/27/2020 Page 2 of 2